- Q1 2024 Relmada Therapeutics Inc Earnings Call TranscriptMay 08, 2024$3.83 (+0.26%)Earnings
- Q4 2023 Relmada Therapeutics Inc Earnings Call TranscriptMar 19, 2024$5.37 (-2.72%)Earnings
- Q3 2023 Relmada Therapeutics Inc Earnings Call TranscriptNov 08, 2023$3 (-1.64%)Earnings
- Q2 2023 Relmada Therapeutics Inc Earnings Call TranscriptAug 08, 2023$2.54 (-3.79%)Earnings
- Relmada Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Relmada Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 Relmada Therapeutics Inc Earnings Call TranscriptMay 11, 2023$3.17 (-3.06%)Earnings
- Q4 2022 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2023$2.32 (-0.85%)Earnings
- Relmada Therapeutics Inc Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder - Corporate Call TranscriptDec 07, 2022
- Q3 2022 Relmada Therapeutics Inc Earnings Call TranscriptNov 10, 2022$5.84 (+1.39%)Earnings
- Q2 2022 Relmada Therapeutics Inc Earnings Call TranscriptAug 11, 2022$27.82 (-4.99%)Earnings
- Relmada Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Q1 2022 Relmada Therapeutics Inc Earnings Call TranscriptMay 05, 2022$22.4 (-7.70%)Earnings
- Q4 2021 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2022$23.33Earnings
- Relmada Therapeutics Inc Results of Human Abuse Potential Study of REL-1017 vs. Ketamine - Corporate Call TranscriptFeb 23, 2022
- Q3 2021 Relmada Therapeutics Inc Earnings Call TranscriptNov 11, 2021$25.66 (+3.22%)Earnings
- Relmada Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 Relmada Therapeutics Inc Earnings Call TranscriptAug 10, 2021$23 (+1.28%)Earnings
- Relmada Therapeutics Inc REL-1017 Clinical Data Update Call TranscriptJul 27, 2021
- Q1 2021 Relmada Therapeutics Inc Earnings Call TranscriptMay 12, 2021$33.61 (-3.81%)Earnings
- Q4 2020 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2021$34.34 (-3.40%)Earnings
Relmada Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Well, thanks, everyone, for joining us. We're really pleased to have the team from Relmada with us, Sergio Traversa, CEO; and Caroline Cotton, Communications Manager. With that, Sergio, maybe we'll start with the pivotal [Rev3 Phase III] trials coming this year.
But before we start with that, maybe just for people who may not be as familiar, if you could remind us on the profile that you've seen so far with REL-1017 -- will make you so excited about it.
Sure. Well, Andrea, first of all, thank you for the invitation and thanks, Goldman Sachs, and good morning all good afternoon for the people that are on the other side on the East Coast. And profile of REL-1017. We're talking about CNS, we are talking about depression and both monotherapy and adjuvant or adjunctive treatment of depression.
The profile, what we have seen in Phase II is the data that we have in our hands that we hope to repeat in the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)